Antibody buy for Piramal
24th December 2021
Submitted by:
Andrew Warmington
India-based CDMO Piramal Pharma has taken a 27.78% equity stake in Yapan Bio of Hyderabad, which provides process development, scale-up and cGMP manufacturing of vaccines and biologics/bio-therapeutics of all kinds, including recombinant and RNA/DNA vaccines, gene therapies and monoclonal antibodies.
The company said that this marks a significant addition to its capabilities in the developing and manufacturing large molecules for human clinical trials. It currently offers integrated payload, conjugation and fill-finish services out of sites in the US and the UK, which these capabilities enhance.